Advertisement
open access
Medical Conferences
Conference Reports
Conference Proceedings
Disease Areas
Medical News
Multimedia
Podcast Channel
Videos
Webinar
About
2024 Medicom Conference Planning
Conference Proceedings
Home
>
Oncology
>
ESMO 2019
ESMO 2019
European Society for Medical Oncology
27 September – 01 October 2019,
Barcelona, Spain
Read the full Report (e-book)
Table of Contents
Colophon
Table of Contents
Featured articles
Letter from the Editor
Editor
Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Esch, Luxembourg
Interview with ESMO President Prof. Josep Tabernero
Expert
Prof. Josep Tabernero, Vall d’Hebron University Hospital, Barcelona, Spain
Breast Cancer
Triple negative breast cancer gets positive news: KEYNOTE-522 interim results
Presented By
Prof. Peter Schmid, Queen Mary University of London, UK
CDK4/6 inhibitors change landscape of breast cancer treatment: 2 studies
Presented By
Prof. Dennis Slamon, Prof. George Sledge, Prof. Nadia Harbeck
Veliparib-chemo combo prolongs survival without disease progression in some advanced breast cancer patients
Presented By
Veronique Diéras, Centre Eugène Marquis, Rennes, France
Lung Cancer
Improved response rates without survival benefit with pembrolizumab in pretreated mesothelioma
Presented By
Dr Sanjay Popat, Royal Marsden Hospital NHS Foundation Trust, UK
Frontline ipilimumab/nivolumab improves OS in advanced NCLSC
Presented By
Prof. Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
First-line osimertinib significantly lengthens OS in NSCLC
Presented By
Prof. Suresh Ramalingam, Emory University, Atlanta, USA
Liquid biopsy to decide the best treatment for NSCLC
Presented By
Dr Shirish Gadgeel, University of Michigan, USA
Melanoma
Long-term data from CheckMate 067
Presented By
Prof. James Larkin, Royal Marsden NHS Foundation Trust, London, UK
Adjuvant nivolumab provides benefit
Presented By
Prof. Jeffrey S. Weber, NYU Langone Medical Center, New York City, USA
Nivolumab+ipilimumab superior to monotherapy for melanoma brain metastases
Presented By
Prof. Georgina Long, Melanoma Institute Australia, Sydney, Australia
GI Cancers
Preoperative chemotherapy for colon cancer
Presented By
Prof. Dion Morton, University of Birmingham, UK
Nivolumab improves OS in advanced oesophageal cancer
Presented By
Prof. Byoung Chul Cho, Yonsei University College of Medicine, South Korea
Liquid biopsy identifies relapse in patients with colorectal cancer after surgery
Presented By
Prof. Julien Taieb, Hopital European Georges Pompidou, France
In hepatocellular carcinoma, CheckMate 459 misses OS endpoint, but some interesting trends emerge
Presented By
Dr Thomas Yau, University of Hong Kong, China
Heavily pre-treated GIST: ripretinib improves PFS
Presented By
Prof. Margaret von Mehren, Fox Chase Cancer Center, USA
FGFR2+ cholangiocarcinoma: pemigatinib active as second-line treatment
Presented By
Prof. Antoine Hollebecque, Gustave Roussy Cancer Center, France
IDH1+ cholangiocarcinoma: phase 3 results show improved PFS
Presented By
Dr Ghassan Abou-Alfa, Memorial Sloan-Kettering Cancer Center, New York, USA
Advanced colorectal cancer and BRAF mutations: triplet combination improves survival
Presented By
Prof. Scott Kopetz, MD Anderson Cancer Center, Houston, USA
Genitourinary Cancers
25% reduction in the risk of death in patients with nmCRPC treated with apalutamide
Presented By
Prof. Matthew Smith, Massachusetts General Hospital, Boston, USA
Enfortumab vedotin and pembrolizumab in advanced bladder cancer: initial results
Presented By
Prof. Christopher Hoimes, Case Comprehensive Cancer Center, Cleveland, USA
PARP inhibition in selected patients slows progression on advanced prostate cancer
Presented By
Prof. Maha Hussain, Northwestern University, Chicago, USA
PFS extension with immunotherapy + chemotherapy in urothelial cancer
Presented By
Dr Enrique Grande, MD Anderson Cancer Centre Madrid, Spain
Third-line in mCRPC: CARD trial
Presented By
Prof. Ronald De Wit, Erasmus University Rotterdam, the Netherlands
Prostate cancer: spare radiotherapy after surgery
Presented By
Prof. Chris Parker, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, UK
Novel mode of action for kidney cancer treatment
Presented By
Prof. Eric Jonasch, MD Anderson Cancer Center, Houston, USA
Gynaecological Cancers
Ovarian cancer patients benefit from combined maintenance therapy
Presented By
Prof. Isabelle Ray-Coquard, Université Claude Bernard, Lyon, France
Combination of PARP inhibition plus chemotherapy in ovarian cancer
Presented By
Robert Coleman, University of Texas, MD Anderson Cancer Center, Houston, USA
PFS benefit with niraparib as first-line maintenance in ovarian cancer
Principal Investigator
Prof. Antonio González Martín, Clinica Universidad de Navarra, Spain
CNS Tumours
Ceritinib in ALK+ NSCLC brain metastases
Presented By
Dr Laura Quan Man Chow, University of Texas at Austin, USA
Adding bevacizumab to temozolomide-based therapy in neuroblastoma
Solid Tumours/Pan-Tumour Data
Mixed data: AMG 510 in tumours with KRASG12C
Presented By
Prof. Ramaswamy Govindan, Washington University, St Louis, USA
DNA profiling of carcinoma of unknown primary should inform treatment
Presented By
Prof. Karim Fizazi, University of Paris Sud, France
Larotrectinib: safe and effective in TRK fusion-positive tumours
Presented By
Dr David Hyman, Memorial Sloan Kettering Cancer Center, New York, USA